Nano-Enabled Combination Therapies Integrating Antioxidants, Peptides, and Hormones for Diabesity Treatment

Kato Jumba K.

Faculty of Science and Technology Kampala International University Uganda

                                                                                                 ABSTRACT
Obesity and type 2 diabetes frequently coexist as “diabesity,” a chronic condition driven by insulin resistance, βcell stress, lipotoxicity, oxidative damage, and metaflammation. Conventional monotherapies that focus on single pathways often produce incomplete or transient benefits, especially in individuals with severe obesity, fatty liver disease and complex cardiovascular risk. Combination regimens that integrate antioxidants, bioactive peptides and metabolic hormones are conceptually attractive because they can simultaneously target redox stress, appetite and energy homeostasis, glucose control and organ protection. However, co-administration of multiple agents in free form is hampered by mismatched pharmacokinetics, off-target toxicity and adherence challenges. Nanotechnology offers a means to co-encapsulate and coordinate these agents within a single platform, enabling synchronized delivery, tissue targeting and controlled release. Nano-enabled combination systems can, in principle, protect labile antioxidants, stabilize peptides and hormones, tune their exposure profiles and direct them toward key metabolic organs such as adipose tissue, liver, skeletal muscle and pancreatic islets. This review discusses the rationale for combining antioxidants, peptides and hormones in diabesity; describes nanocarrier platforms suitable for their co-delivery; and examines how redox modulation, peptide signaling and endocrine control can be integrated at the nanoscale. Preclinical examples are highlighted alongside safety, manufacturing and regulatory considerations. Finally, the article outlines future directions, including stimulus-responsive and patient-tailored nanoformulations that complement lifestyle change and emerging incretin therapies in the personalized management of diabesity.

Keywords: Nanomedicine; diabesity; combination therapy; antioxidants; peptide–hormone co-delivery

CITE AS: Kato Jumba K. (2026). Nano-Enabled Combination Therapies Integrating Antioxidants, Peptides, and Hormones for Diabesity Treatment. NEWPORT INTERNATIONAL JOURNAL OF PUBLIC HEALTH AND PHARMACY,7(1):62-69.
https://doi.org/10.59298/NIJPP/2026/716269